Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad/PSA Vaccine in Hormone-Refractory Prostate Cancer
NCT00583024Phase 2Completed
- Start
- Dec 2007
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adenovirus PSA vaccine in prostate cancer (PCa). Primary endpoints: PSA Doubling Time at 18 months and Anti-PSA Immune Response at 18 months. Started Dec 2007; status: completed.
02
Drugs
adenovirus PSA vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00583024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00583024.